LBRX LB Corp: Price-to-Projected Revenue Ratio

Corporate emblem and logo of LB Pharmaceuticals, Inc. (LBRX)

LB Pharmaceuticals Inc relies on a diversified pool of international CMOs for the synthesis of complex compounds. The projected P/S multiple, with a metric value of , reflects the dynamics of market expectations. Patents for schizophrenia medications ensure stable revenue, while the non-cyclical demand for antipsychotics makes the business resilient to GDP fluctuations, linking growth to the success of clinical trials.

LB Pharmaceuticals, Inc. - LBRX Price-to-Projected Revenue Ratio (period 07/04/2022 - 11/13/2026)

Financial and market metric breakdowns for LB Corp (LBRX)

- market price and analyst price targets:
Price Chart LB Pharmaceuticals|LBRX - Average Forecast Price
- company stock capitalization data:
Market Value LB Corp|LBRX - Total Company Value
- book value of equity indicators:
Book Value per Share LB Pharmaceuticals|LBRX - Company Book Value|Market Cap to Net Assets Ratio lbpharma.us|LBRX - Aggregate Asset Value
- business debt structure and liquidity details:
Debt to Equity LB Pharmaceuticals Inc|LBRX - Long-Term Liabilities to Equity|Short-Term Debt to Capital LB Pharmaceuticals Inc|LBRX - Aggregate Debt Obligations|Debts to Book Capitalization LB Corp|LBRX - Company Long-Term Debts|Company Short-Term Debt LB Pharmaceuticals|Quick Liquidity lbpharma.us
- financial results and valuation multiples details:
LBRX - Net Income|Projected Future Earnings LB Pharmaceuticals Inc|LBRX - P/E Multiple|Forward P/E Multiple LB Pharma|LBRX - Price/Earnings to Growth Multiple|EV/EBITDA Multiple LB Corp|LBRX - Profit before interest, taxes and amortization|Net earnings per share for the last 12 months LB Pharmaceuticals|LBRX - Net earnings per share (EPS TTM)|Year-over-year net earnings per share growth for the last 12 months lbpharma.us|LBRX - Net earnings per one share growth for the current year|Earnings growth forecast for next year LB Pharmaceuticals Inc
- sales revenue and business income indicators:
LBRX - Company Gross Revenue|Projected Sales Volume LB Pharmaceuticals|LBRX - Market Cap to Revenue|Forward P/S Multiple LB Corp
Summary company analysis:LB Pharmaceuticals LBRX
Original product of LB Corp

The forward P/S measures the ratio of the current market value of LB Pharmaceuticals Inc (LBRX) to expected sales, allowing for an assessment of the degree of optimism priced in amid rising operating expenses. By analyzing the forward P/S based on forecasts, an investor determines the resilience of the capitalization to risks, which is critical for LB Pharmaceuticals Inc (LBRX) during the implementation of robotic biomolecule screening to accelerate drug development.

Competitors of LB Pharmaceuticals Inc

Price-to-Projected Revenue Ratio Alkermes ALKS|Avadel Pharmaceuticals PLC (AVDL) - Market Cap to Future Revenue Ratio|ATAI - Price-to-Projected Revenue Ratio|GHRS: Price-to-Projected Revenue Ratio|MNMD: Forward P/S Multiple|CMPS (compasspathways.com) - Price-to-Projected Revenue Ratio|Forward Price-to-Revenue Multiple DRUG|VNDA: Forward Price to Sales|Price-to-Projected Revenue Ratio Cybin Inc. (CYBN)|ANRO: Future Price to Revenue|Forward P/S Multiple NRXP (NRx Pharmaceuticals)|Forward Price to Sales CING|Silo Pharma, Inc. - Forward P/S Multiple|CPHI - Forward P/S Multiple|Clearmind Medicine (CMND) - Price-to-Projected Revenue Ratio|Psyence Bio - Forward Price to Sales|Price-to-Projected Revenue Ratio SciSparc Ltd|Forward Price-to-Revenue Multiple seelostherapeutics.com (SEEL)|Forward P/S Multiple VRPX|Forward P/S Multiple Karuna Therapeutics Inc (KRTX)